PMV Pharmaceuticals, Inc. PMVP
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
Day range unavailable
- YTD
- +4.80%
- 1 year
- -6.43%
- Open
- —
- Prev close
- 1.31
- Mkt cap
- 98.92M
- Vol
- 0
- Avg vol
- 686.55K
- EPS
- -1.42
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -0.96
- Beta
- 1.48
- Short ratio
- 5.17
- Inst. own
- 83.89%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 1.61
- 200-d avg
- 1.65
- 1y target
- 5.80
News
2 months ago benzinga.com
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
PMV Pharmaceuticals reports 46% ORR in Phase 2 trial for ovarian cancer drug rezatapopt. NDA submission planned for Q1 2027.
2 months ago benzinga.com
Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Shares of Pyxis Tankers Inc (NASDAQ:PXS) rose sharply in pre-market trading after the company reported better-than-expected earnings for the second quarter. The company posted quarterly earnings of…
-
2 months ago benzinga.com
PMV Pharma Q2 EPS $(0.34) Beats $(0.39) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 17.07 percent increase over losses of $(0.41)…
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
5 months ago benzinga.com
Oppenheimer Maintains Outperform on PMV Pharmaceuticals, Lowers Price Target to $5
Oppenheimer analyst Jeff Jones maintains PMV Pharmaceuticals (NASDAQ:PMVP) with a Outperform and lowers the price target from $6 to $5.
-
5 months ago benzinga.com
PMV Pharma Q1 EPS $(0.34) Beats $(0.39) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is unchanged from the same period last year.
-
6 months ago benzinga.com
PMV Pharmaceuticals Appoints Laurie Stelzer As Board Chair, Effective June 4, Succeeding Rich Heyman
PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today…
-
8 months ago benzinga.com
PMV Pharma Q4 EPS $(0.34) Beats $(0.41) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.41) by 16.46 percent. This is a 24.44 percent increase over losses of $(0.45)…
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
8 months ago benzinga.com
PMV Pharmaceuticals Announces NEJM Publication Showing Phase 1 Rezatapopt Demonstrates Safety And Antitumor Activity In TP53 Y220C–Mutated Cancers
PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today…
-
11 months ago benzinga.com
PMV Pharma Q3 EPS $(0.40), Inline
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.40) per share which met the analyst consensus estimate. This is a 8.11 percent decrease over losses of $(0.37) per share from the same period…
-
1 year ago benzinga.com
PMV Pharmaceuticals Announces Updated Data From The Phase 2 Pivotal Portion Of The Ongoing PYNNACLE Clinical Trial In Patients With Advanced Solid Tumors Harboring A TP53 Y220C Mutation; Overall Response Rate Of 34% (35/103 Patients) Per Investigator Assessment According To Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1, Including Confirmed And Unconfirmed Responses
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning…
-
1 year ago benzinga.com
PMV Pharmaceuticals To Present Rezatapopt Pivotal Phase 2 Initial Analysis And Natural History Study Results
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer…
1 year ago benzinga.com
Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types
PMV Pharma's Phase 2 trial shows 33% response in TP53 Y220C-mutated tumors, with ovarian cancer achieving a 43% response rate in interim results.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
PMV Pharma Announces Interim Data From Phase 2 Pivotal Portion Of PYNNACLE Clinical Trial; Plans To Submit NDA For Platinum Resistant/Refractory Ovarian Cancer By End Of Q1 2027
PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
PMV Pharma Q2 EPS $(0.41) Misses $(0.38) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.38) by 7.05 percent. This is a 1950 percent decrease over losses of $(0.02)…
-
1 year ago benzinga.com
PMV Pharma Q1 EPS $(0.34) Beats $(0.37) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 8.11 percent. This is a 13.33 percent decrease over losses of $(0.30)…
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
-
1 year ago benzinga.com
PMV Pharma FY 2024 GAAP EPS $(1.14) Misses $(1.08) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.08) by 5.56 percent.
-
1 year ago benzinga.com
PMV Pharma Q3 EPS $(0.37) Misses $(0.35) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.35) by 5.71 percent. This is a 8.82 percent decrease over losses of $(0.34)…
-
2 years ago benzinga.com
HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
-
2 years ago benzinga.com
PMV Pharma Q2 EPS $(0.02) Beats $(0.33) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.33) by 93.94 percent. This is a 94.74 percent increase over losses of $(0.38)…
-
2 years ago benzinga.com
HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
-
2 years ago benzinga.com
Foundation Medicine and PMV Pharma Partner to Develop Genomic Profiling for TP53 Mutation Therapy, Targets TP53 Mutation in Advanced Cancers with Investigational Therapy Rezatapopt
Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, ", PMV Pharma", )))) today announced a partnership to develop Foundation Medicine's tissue-based comprehensive genomic profiling
-
2 years ago benzinga.com
HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
-
2 years ago benzinga.com
Craig-Hallum Initiates Coverage On PMV Pharma with Buy Rating, Announces Price Target of $6
Craig-Hallum analyst Albert Lowe initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating and announces Price Target of $6.
-
2 years ago benzinga.com
PMV Pharma Q1 EPS $(0.30) Beats $(0.37) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.37) by 18.92 percent. This is a 28.57 percent increase over losses of $(0.42)…
-
2 years ago benzinga.com
Jefferies Initiates Coverage On PMV Pharma with Buy Rating, Announces Price Target of $5
Jefferies analyst Kambiz Yazdi initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating and announces Price Target of $5.
-
2 years ago benzinga.com
PMV Pharmaceuticals PYNNACLE Phase I Data Of Rezatapopt In Advanced Ovarian Cancer Featured In Oral Presentation At 2024 SGO Annual Meeting On Women's Cancer
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation…
-
2 years ago benzinga.com
HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
-
2 years ago benzinga.com
PMV Pharmaceuticals FY23 EPS $(1.44) Vs $(1.61) YoY
Fiscal Year 2023 Financial ResultsAs of December 31, 2023, PMV Pharma had $228.6 million in cash, cash equivalents, and marketable securities, compared to $243.5 million at December 31, 2022. Net…
-
2 years ago benzinga.com
PMV Pharmaceuticals Plans Workforce Reduction Of Approximately 30%; Reveals Prioritization Of PC14586 Development And Focused Discovery Research Efforts Results
Unaudited cash, cash equivalents, and marketable securities totaling approximately $229 million as of December 31, 2023, combined with cost savings from workforce reduction, is expected to extend…
-
2 years ago benzinga.com
Ladenburg Thalmann Initiates Coverage On PMV Pharma with Buy Rating, Announces Price Target of $7
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating and announces Price Target of $7.
-
2 years ago benzinga.com
PMV Pharma Q3 EPS $(0.34) Beats $(0.45) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.45) by 24.44 percent. This is a 15 percent increase over losses of $(0.40) per…
-
3 years ago benzinga.com
HC Wainwright & Co. Maintains Buy on PMV Pharma, Lowers Price Target to $5
HC Wainwright & Co. analyst Robert Burns maintains PMV Pharma (NASDAQ:PMVP) with a Buy and lowers the price target from $29 to $5.
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
3 years ago benzinga.com
Why Belden Shares Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreement for the acquisition of NextTrip Holdings, Inc.
-
3 years ago benzinga.com
Precision Oncology PMV Pharmaceuticals Reveals Early Data From Cancer Study In Pretreated Patients
PMV Pharmaceuticals Inc (NASDAQ: PMVP) announced updated Phase 1 results from its ongoing Phase 1/2 PYNNACLE trial that showed PC14586 achieved efficacy in heavily pretreated patients across multiple…
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
3 years ago benzinga.com
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With A TP53 Y220C Mutation
Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsConfirmed responses observed in…
-
3 years ago benzinga.com
PMV Pharmaceuticals To Present Updated Phase 1 Data On PC14586 At The 2023 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics And Host A KOL Webinar
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it will…
-
3 years ago benzinga.com
Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions.
-
3 years ago benzinga.com
PMV Pharmaceuticals To Present Updated Phase 1 Data On PC14586 At The 2023 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have…
-
3 years ago benzinga.com
HC Wainwright & Co. Maintains Buy on PMV Pharma, Lowers Price Target to $29
HC Wainwright & Co. analyst Robert Burns maintains PMV Pharma (NASDAQ:PMVP) with a Buy and lowers the price target from $35 to $29.
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
3 years ago benzinga.com
Why Cutera Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Wednesday's Session
Gainers Tango Therapeutics, Inc. (NASDAQ: TNGX) climbed 85.2% to $7.09 after gaining 11% on Tuesday. Tango Therapeutics recently posted a narrower quarterly loss.